OA12375A - The hydrochloride salt of 5-Ä4-Ä2-(N-methyl-N-(2-pyridyl)amino)ethoxyÜbenzylÜthiazolidine-2,4-dione. - Google Patents

The hydrochloride salt of 5-Ä4-Ä2-(N-methyl-N-(2-pyridyl)amino)ethoxyÜbenzylÜthiazolidine-2,4-dione. Download PDF

Info

Publication number
OA12375A
OA12375A OA1200300068A OA1200300068A OA12375A OA 12375 A OA12375 A OA 12375A OA 1200300068 A OA1200300068 A OA 1200300068A OA 1200300068 A OA1200300068 A OA 1200300068A OA 12375 A OA12375 A OA 12375A
Authority
OA
OAPI
Prior art keywords
accordance
compound
hydrochîoride
dione
pyridyl
Prior art date
Application number
OA1200300068A
Other languages
English (en)
Inventor
Andrew Simon Craig
Michael Millan
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of OA12375A publication Critical patent/OA12375A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
OA1200300068A 2000-09-06 2001-09-05 The hydrochloride salt of 5-Ä4-Ä2-(N-methyl-N-(2-pyridyl)amino)ethoxyÜbenzylÜthiazolidine-2,4-dione. OA12375A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0021865.1A GB0021865D0 (en) 2000-09-06 2000-09-06 Novel pharmaceutical

Publications (1)

Publication Number Publication Date
OA12375A true OA12375A (en) 2004-03-19

Family

ID=9898953

Family Applications (1)

Application Number Title Priority Date Filing Date
OA1200300068A OA12375A (en) 2000-09-06 2001-09-05 The hydrochloride salt of 5-Ä4-Ä2-(N-methyl-N-(2-pyridyl)amino)ethoxyÜbenzylÜthiazolidine-2,4-dione.

Country Status (35)

Country Link
US (3) US20040034066A1 (cs)
EP (1) EP1315723B1 (cs)
JP (1) JP2004508369A (cs)
KR (1) KR100770513B1 (cs)
CN (1) CN100558717C (cs)
AP (1) AP1715A (cs)
AT (1) ATE300538T1 (cs)
AU (2) AU8428401A (cs)
BG (1) BG107607A (cs)
BR (1) BR0113713A (cs)
CA (1) CA2421213A1 (cs)
CY (1) CY1105252T1 (cs)
CZ (1) CZ302125B6 (cs)
DE (1) DE60112310T2 (cs)
DK (1) DK1315723T3 (cs)
DZ (1) DZ3475A1 (cs)
EA (1) EA004296B1 (cs)
EC (1) ECSP034505A (cs)
ES (1) ES2244647T3 (cs)
GB (1) GB0021865D0 (cs)
HK (1) HK1057749A1 (cs)
HU (1) HUP0300938A3 (cs)
IL (2) IL154724A0 (cs)
MA (1) MA25908A1 (cs)
MX (1) MXPA03001956A (cs)
NO (1) NO324020B1 (cs)
NZ (1) NZ524548A (cs)
OA (1) OA12375A (cs)
PL (1) PL360578A1 (cs)
PT (1) PT1315723E (cs)
SI (1) SI1315723T1 (cs)
SK (1) SK2632003A3 (cs)
UA (1) UA74003C2 (cs)
WO (1) WO2002020519A1 (cs)
ZA (1) ZA200301809B (cs)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE39384E1 (en) 1993-09-01 2006-11-07 Smithkline Beecham P.L.C. Substituted thiazolidinedione derivatives
GB0006133D0 (en) 2000-03-14 2000-05-03 Smithkline Beecham Plc Novel pharmaceutical
DE102005034406A1 (de) * 2005-07-22 2007-02-01 Ratiopharm Gmbh Neue Salze von Rosiglitazon
US7435741B2 (en) * 2006-05-09 2008-10-14 Teva Pharmaceutical Industries, Ltd. 2-N{5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2,4-thiazolidinedione} butanedioic acid, methods of preparation and compositions with rosiglitazone maleate
JP5063714B2 (ja) * 2010-01-29 2012-10-31 シャープ株式会社 画像読取装置及び画像形成装置
EP2508525A1 (en) 2011-04-05 2012-10-10 Bayer Pharma Aktiengesellschaft Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts
RU2487132C1 (ru) * 2012-07-23 2013-07-10 Общество с ограниченной ответственностью "Метаген" Производные циклических 5-нитропиридин-2-ил-тиоалкенил-4-дитиокарбаматов, обладающие противогрибковой активностью, и их применение

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0842925A1 (en) * 1987-09-04 1998-05-20 Beecham Group Plc Substituted thiazolidinedione derivatives
US6288095B1 (en) * 1987-09-04 2001-09-11 Beecham Group P.L.C. Compounds
GB9124513D0 (en) * 1991-11-19 1992-01-08 Smithkline Beecham Plc Novel process
GB9218830D0 (en) * 1992-09-05 1992-10-21 Smithkline Beecham Plc Novel compounds
US5741803A (en) * 1992-09-05 1998-04-21 Smithkline Beecham Plc Substituted thiazolidinedionle derivatives
US5874454A (en) * 1993-09-15 1999-02-23 Warner-Lambert Company Use of thiazolidinedione derivatives in the treatment of polycystic ovary syndrome, gestational diabetes and disease states at risk for progressing to noninsulin-dependent diabetes mellitus
DK0896182T3 (da) * 1997-07-17 2002-07-29 Interlemo Holding Sa Sammenkoblingssystem
CN1183130C (zh) * 1999-09-24 2005-01-05 中国人民解放军军事医学科学院毒物药物研究所 噻唑烷类衍生物及其医药用途
GB0006133D0 (en) * 2000-03-14 2000-05-03 Smithkline Beecham Plc Novel pharmaceutical
US6627646B2 (en) * 2001-07-17 2003-09-30 Sepracor Inc. Norastemizole polymorphs

Also Published As

Publication number Publication date
BR0113713A (pt) 2004-07-06
AU8428401A (en) 2002-03-22
WO2002020519A1 (en) 2002-03-14
IL154724A (en) 2009-07-20
UA74003C2 (en) 2005-10-17
ES2244647T3 (es) 2005-12-16
MA25908A1 (fr) 2003-10-01
CZ302125B6 (cs) 2010-11-03
KR100770513B1 (ko) 2007-10-25
JP2004508369A (ja) 2004-03-18
AP1715A (en) 2007-02-28
DZ3475A1 (fr) 2002-03-14
DK1315723T3 (da) 2005-10-24
CZ2003615A3 (cs) 2003-11-12
AU2001284284B2 (en) 2005-08-04
AP2003002758A0 (en) 2003-06-30
EP1315723B1 (en) 2005-07-27
IL154724A0 (en) 2003-10-31
NO20031020D0 (no) 2003-03-05
HUP0300938A3 (en) 2005-04-28
ZA200301809B (en) 2004-04-19
ATE300538T1 (de) 2005-08-15
MXPA03001956A (es) 2003-06-24
US20070191435A1 (en) 2007-08-16
KR20030027118A (ko) 2003-04-03
NO324020B1 (no) 2007-07-30
EA004296B1 (ru) 2004-02-26
NZ524548A (en) 2004-10-29
PT1315723E (pt) 2005-11-30
CA2421213A1 (en) 2002-03-14
BG107607A (bg) 2003-12-31
US20050282867A1 (en) 2005-12-22
EA200300345A1 (ru) 2003-08-28
PL360578A1 (en) 2004-09-06
ECSP034505A (es) 2003-06-25
CN100558717C (zh) 2009-11-11
DE60112310T2 (de) 2006-02-09
CY1105252T1 (el) 2010-03-03
GB0021865D0 (en) 2000-10-18
US20040034066A1 (en) 2004-02-19
NO20031020L (no) 2003-05-06
EP1315723A1 (en) 2003-06-04
DE60112310D1 (de) 2005-09-01
HUP0300938A2 (hu) 2003-11-28
SK2632003A3 (en) 2003-12-02
CN1366520A (zh) 2002-08-28
SI1315723T1 (en) 2005-10-31
HK1057749A1 (en) 2004-04-16

Similar Documents

Publication Publication Date Title
US20060040993A1 (en) 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione Mesylate salt
US20070191435A1 (en) Hydrochloride salt of 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione
EP1446404B1 (en) Rosiglitazone edisylates and their use as antidiabetics
AU2001284284A1 (en) The hydrochloride salt of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl] thiazolidine-2,4-dione
EP1315724B1 (en) A thiazolidinedione derivative and its use as antidiabetic
US20040014791A1 (en) Thiazolidinedione derivative and its use as antidiabetic
US20040014790A1 (en) Tartrate salt of thiazolidinedione derivative
US20040029926A1 (en) Thiazolidinone nitrate salt
AU2001276508A1 (en) Tartrate salts of thiazolidinedione derivative
EP1448559B1 (en) 5-(4-(2-(n-methyl-n-(2-pyridyl)amino)ethoxy)benzyl)thiazolidine-2,4-dione benzenesulfonate; process for its preparation; polymorphs i, ii and iii thereof; and its use as pharmaceutical active ingredient
US20040038968A1 (en) Thiazolidinedione derivative and its use as antidiabetic
US20040102485A1 (en) Tartrate salt of thiazolidinedione derivative
WO2003053963A1 (en) Novel pharmaceutical